• Kevin A Hay, Jordan Gauthier, Alexandre V Hirayama, Jenna M Voutsinas, Qian Wu, Daniel Li, Ted A Gooley, Sindhu Cherian, Xueyan Chen, Barbara S Pender, Reed M Hawkins, Aesha Vakil, Rachel N Steinmetz, Gary Schoch, Aude G Chapuis, Brian G Till, Hans-Peter Kiem, Jorge D Ramos, Mazyar Shadman, Ryan D Cassaday, Utkarsh H Acharya, Stanley R Riddell, David G Maloney, and Cameron J Turtle.
• Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
• Blood. 2019 Apr 11; 133 (15): 1652-1663.

AbstractAutologous T cells engineered to express a CD19-specific chimeric antigen receptor (CAR) have produced impressive minimal residual disease-negative (MRD-negative) complete remission (CR) rates in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). However, the factors associated with durable remissions after CAR T-cell therapy have not been fully elucidated. We studied patients with relapsed/refractory B-ALL enrolled in a phase 1/2 clinical trial evaluating lymphodepletion chemotherapy followed by CD19 CAR T-cell therapy at our institution. Forty-five (85%) of 53 patients who received CD19 CAR T-cell therapy and were evaluable for response achieved MRD-negative CR by high-resolution flow cytometry. With a median follow-up of 30.9 months, event-free survival (EFS) and overall survival (OS) were significantly better in the patients who achieved MRD-negative CR compared with those who did not (median EFS, 7.6 vs 0.8 months; P < .0001; median OS, 20.0 vs 5.0 months; P = .014). In patients who achieved MRD-negative CR by flow cytometry, absence of the index malignant clone by IGH deep sequencing was associated with better EFS (P = .034). Stepwise multivariable modeling in patients achieving MRD-negative CR showed that lower prelymphodepletion lactate dehydrogenase concentration (hazard ratio [HR], 1.38 per 100 U/L increment increase), higher prelymphodepletion platelet count (HR, 0.74 per 50 000/μL increment increase), incorporation of fludarabine into the lymphodepletion regimen (HR, 0.25), and allogeneic hematopoietic cell transplantation (HCT) after CAR T-cell therapy (HR, 0.39) were associated with better EFS. These data allow identification of patients at higher risk of relapse after CAR T-cell immunotherapy who might benefit from consolidation strategies such as allogeneic HCT. This trial was registered at www.clinicaltrials.gov as #NCT01865617.© 2019 by The American Society of Hematology.

22 keywords...

hide…